Histone deacetylation meets miRNA: epigenetics and post-transcriptional regulation in cancer and chronic diseases

Bibliography

• Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 2007;1(1):19-25
   PubMed Web of Science ®Google Scholar
• Kiesslich T, Pichler M, Neureiter D. Epigenetic control of epithelial-mesenchymal-transition in human cancer. Mol Clin Oncol 2013;1(1):3-11
   PubMedGoogle Scholar
• Stasevich TJ, Hayashi-Takanaka Y, Sato Y, et al. Regulation of RNA polymerase II activation by histone acetylation in single living cells. Nature 2014;516(7530):272-5
   PubMed Web of Science ®Google Scholar
• Sawa H, Murakami H, Ohshima Y, et al. Histone deacetylase inhibitors such as sodium butyrate and trichostatin A induce apoptosis through an increase of the bcl-2-related protein Bad. Brain Tumor Pathol 2001;18:109-14
   PubMedGoogle Scholar
• Wilting RH, Yanover E, Heideman MR, et al. Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis. EMBO J 2010;29:2586-97
   PubMed Web of Science ®Google Scholar
• Brehm A, Miska EA, McCance DJ, et al. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 1998;391:597-601
   PubMed Web of Science ®Google Scholar
• Bernstein BE, Tong JK, Schreiber SL. Genomewide studies of histone deacetylase function in yeast. Proc Natl Acad Sci USA 2000;97:13708-13
   PubMed Web of Science ®Google Scholar
• Medina V, Edmonds B, Young GP, et al. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res 1997;57:3697-707
   PubMed Web of Science ®Google Scholar
• Li Z, Zhu WG. Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications. Int J Biol Sci 2014;10(7):757-70
   PubMed Web of Science ®Google Scholar
• Stintzing S, Kemmerling R, Kiesslich T, et al. Myelodysplastic syndrome and histone deacetylase inhibitors: “to be or not to be acetylated”? J Biomed Biotechnol 2011;2011:214143
   Google Scholar
• Lujambio A, Calin GA, Villanueva A, et al. DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci USA 2008;105(36):13556-61
   PubMed Web of Science ®Google Scholar
• Ropero S, Fraga MF, Ballestar E, et al. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet 2006;38(5):566-9
   PubMed Web of Science ®Google Scholar
• Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: what are the cancer relevant targets? Cancer Lett 2009;277(1):8-21
   PubMed Web of Science ®Google Scholar
• Millard CJ, Watson PJ, Celardo I, et al. Class I HDACs share a common mechanism of regulation by inositol phosphates. Mol Cell 2013;51(1):57-67
   PubMed Web of Science ®Google Scholar
• Kaluza D, Kroll J, Gesierich S, et al. Histone deacetylase 9 promotes angiogenesis by targeting the antiangiogenic microRNA-17-92 cluster in endothelial cells. Arterioscler Thromb Vasc Biol 2013;33(3):533-43
   PubMed Web of Science ®Google Scholar
• Morris MJ, Monteggia LM. Unique functional roles for class I and class II histone deacetylases in central nervous system development and function. Int J Dev Neurosci 2013;31(6):370-81
   PubMed Web of Science ®Google Scholar
• Yuan H, Su L, Chen WY. The emerging and diverse roles of sirtuins in cancer: a clinical perspective. Onco Targets Ther 2013;6:1399-416
   PubMed Web of Science ®Google Scholar
• de Oliveira MV, Andrade JM, Paraíso AF, Santos SH. Sirtuins and cancer: new insights and cell signaling. Cancer Invest 2013;31(10):645-53
   PubMed Web of Science ®Google Scholar
• Deubzer HE, Schier MC, Oehme I, et al. HDAC11 is a novel drug target in carcinomas. Int J Cancer 2013;132(9):2200-8
   PubMed Web of Science ®Google Scholar
• Barneda-Zahonero B, Parra M. Histone deacetylases and cancer. Mol Oncol 2012;6(6):579-89
   PubMed Web of Science ®Google Scholar
• Wendtner CM. Cocktail of eternity: HDAC meets miR. Blood 2012;119(5):1095-6
   PubMed Web of Science ®Google Scholar
• Chatterjee N, Wang WL, Conklin T, et al. Histone deacetylase inhibitors modulate miRNA and mRNA expression, block metaphase, and induce apoptosis in inflammatory breast cancer cells. Cancer Biol Ther 2013;14(7):658-71
   PubMed Web of Science ®Google Scholar
• Noonan EJ, Place RF, Pookot D, et al. miR-449a targets HDAC-1 and induces growth arrest in prostate cancer Function of miR-449a in prostate cancer. Oncogene 2009;28:1714-24
   PubMed Web of Science ®Google Scholar
• Zhao J, Lammers P, Torrance CJ, Bader AG. TP53-independent function of miR-34a via HDAC1 and p21(CIP1/WAF1.). Mol Ther 2013;21(9):1678-86
   PubMed Web of Science ®Google Scholar
• Nalls D, Tang SN, Rodova M, et al. Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. PLoS ONE 2011;6(8):e24099
   PubMed Web of Science ®Google Scholar
• Lodrini M, Oehme I, Schroeder C, et al. MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma. Nucleic Acids Res 2013;41(12):6018-33
   PubMed Web of Science ®Google Scholar
• Chen CQ, Chen CS, Chen JJ, et al. Histone deacetylases inhibitor trichostatin A increases the expression of Dleu2/miR-15a/16-1 via HDAC3 in non-small cell lung cancer. Mol Cell Biochem 2013;383(1-2):137-48
   PubMed Web of Science ®Google Scholar
• Wang Y, Toh HC, Chow P, et al. MicroRNA-224 is up-regulated in hepatocellular carcinoma through epigenetic mechanisms. FASEB J. 2012;26(7):3032-41
   Google Scholar
• Sandhu SK, Volinia S, Costinean S, et al. miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the Eμ-miR-155 transgenic mouse model. Proc Natl Acad Sci USA 2012;109(49):20047-52
   PubMed Web of Science ®Google Scholar
• Winbanks CE, Wang B, Beyer C, et al. TGF-beta regulates miR-206 and miR-29 to control myogenic differentiation through regulation of HDAC4. J Biol Chem 2011;286(16):13805-14
   PubMed Web of Science ®Google Scholar
• Winbanks CE, Beyer C, Hagg A, et al. miR-206 represses hypertrophy of myogenic cells but not muscle fibers via inhibition of HDAC4. PLoS One 2013;8(9):e73589
   PubMed Web of Science ®Google Scholar
• Wang Z, Qin G, Zhao TC. HDAC4: mechanism of regulation and biological functions. Epigenomics 2014;6(1):139-50
   PubMed Web of Science ®Google Scholar
• Li H, Xie H, Liu W, et al. A novel microRNA targeting HDAC5 regulates osteoblast differentiation in mice and contributes to primary osteoporosis in humans. J Clin Invest 2009;119(12):3666-77
   PubMed Web of Science ®Google Scholar
• Simon D, Laloo B, Barillot M, et al. A mutation in the 3’-UTR of the HDAC6 gene abolishing the post-transcriptional regulation mediated by hsa-miR-433 is linked to a new form of dominant X-linked chondrodysplasia. Hum Mol Genet 2010;19(10):2015-27
   PubMed Web of Science ®Google Scholar
• Huang S, Wang S, Bian C, et al. Upregulation of miR-22 promotes osteogenic differentiation and inhibits adipogenic differentiation of human adipose tissue-derived mesenchymal stem cells by repressing HDAC6 protein expression. Stem Cells Dev. 2012;21(13):2531-40
   Google Scholar
• Lwin T, Zhao X, Cheng F, et al. A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas. J Clin Invest 2013;123(11):4612-26
   PubMed Web of Science ®Google Scholar
• Kai Y, Peng W, Ling W, et al. Reciprocal effects between microRNA-140-5p and ADAM10 suppress migration and invasion of human tongue cancer cells. Biochem Biophys Res Commun 2014;448(3):308-14
   PubMed Web of Science ®Google Scholar
• Yu XF, Zou J, Bao ZJ, Dong J. miR-93 suppresses proliferation and colony formation of human colon cancer stem cells. World J Gastroenterol 2011;17(42):4711-17
   PubMed Web of Science ®Google Scholar
• Sekiya T, Adachi S, Kohu K, et al. Identification of BMP and activin membrane-bound inhibitor (BAMBI), an inhibitor of transforming growth factor-beta signaling, as a target of the beta-catenin pathway in colorectal tumor cells. J Biol Chem 2004;279(8):6840-6
   PubMed Web of Science ®Google Scholar
• Elyada E, Pribluda A, Goldstein RE, et al. CKIα ablation highlights a critical role for p53 in invasiveness control. Nature 2011;470(7334):409-13
   PubMed Web of Science ®Google Scholar
• Konsavage WMJr, Yochum GS. The myc 3’ wnt-responsive element suppresses colonic tumorigenesis. Mol Cell Biol 2014;34(9):1659-69
   PubMed Web of Science ®Google Scholar
• Piard F, Martin L, Chapusot C, et al. [Genetic pathways in colorectal cancer: interest for the pathologist]. Ann Pathol 2002;22(4):277-88
   PubMed Web of Science ®Google Scholar
• Sierra J, Yoshida T, Joazeiro CA, Jones KA. The APC tumor suppressor counteracts beta-catenin activation and H3K4 methylation at Wnt target genes. Genes Dev 2006;20(5):586-600
   PubMed Web of Science ®Google Scholar
• Kaluza D, Kroll J, Gesierich S, et al. Histone deacetylase 9 promotes angiogenesis by targeting the antiangiogenic microRNA-17-92 cluster in endothelial cells. Arterioscler Thromb Vasc Biol 2013;33(3):533-43
   PubMed Web of Science ®Google Scholar
• Lin L, Hou J, Ma F, et al. Type I IFN inhibits innate IL-10 production in macrophages through histone deacetylase 11 by downregulating microRNA-145. J Immunol 2013;191(7):3896-904
   PubMed Web of Science ®Google Scholar
• Shi B, Xu W. The development and potential clinical utility of biomarkers for HDAC inhibitors. Drug Discov Ther 2013;7(4):129-36
   PubMedGoogle Scholar
• New M, Olzscha H, La Thangue NB. HDAC. inhibitor-based therapies: can we interpret the code? Mol Oncol 2012;6(6):637-56
   PubMed Web of Science ®Google Scholar
• Saccone V, Consalvi S, Giordani L, et al. HDAC-regulated myomiRs control BAF60 variant exchange and direct the functional phenotype of fibro-adipogenic progenitors in dystrophic muscles. Genes Dev 2014;28(8):841-57
   PubMed Web of Science ®Google Scholar
• Cheng TL, Wang Z, Liao Q, et al. MeCP2 suppresses nuclear microRNA processing and dendritic growth by regulating the DGCR8/Drosha complex. Dev Cell 2014;28(5):547-60
   PubMed Web of Science ®Google Scholar
• Pushpavalli SN, Ramaiah MJ, Lavanya A, et al. Imidazo-benzothiazoles a potent microRNA modulator involved in cell proliferation. Bioorg Med Chem Lett 2012;22(20):6418-24
   PubMed Web of Science ®Google Scholar
• Hughes DP. How the NOTCH pathway contributes to the ability of osteosarcoma cells to metastasize. Cancer Treat Res 2009;152:479-96
   PubMedGoogle Scholar
• Delcuve GP, Khan DH, Davie JR. Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors. Clin Epigenetics 2012;4(1):5
   PubMed Web of Science ®Google Scholar
• Ververis K, Hiong A, Karagiannis TC, Licciardi PV. Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics 2013;7:47-60
   PubMedGoogle Scholar
• Muinelo-Romay L, Villar-Portela S, Cuevas Alvarez E, et al. α(1,6)Fucosyltransferase expression is an independent prognostic factor for disease-free survival in colorectal carcinoma. Hum Pathol 2011;42(11):1740-50
   PubMed Web of Science ®Google Scholar
• Bernardi C, Soffientini U, Piacente F, Tonetti MG. Effects of microRNAs on fucosyltransferase 8 (FUT8) expression in hepatocarcinoma cells. PLoS One 2013;8(10):e76540
   PubMedGoogle Scholar
• Mizuno S, Yasuo M, Bogaard HJ, et al. Inhibition of histone deacetylase causes emphysema. Am J Physiol Lung Cell Mol Physiol 2011;300(3):L402-13
   PubMed Web of Science ®Google Scholar
• Ji Q, Hao X, Zhang M, et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS ONE 2009;4(8):e6816
   PubMed Web of Science ®Google Scholar
• Zhao J, Lammers P, Torrance CJ, Bader AG. TP53-independent function of miR-34a via HDAC1 and p21(CIP1/WAF1.). Mol Ther 2013;21(9):1678-86
   PubMed Web of Science ®Google Scholar
• Zhang HS, Chen XY, Wu TC, et al. MiR-34a is involved in Tat-induced HIV-1 long terminal repeat (LTR) transactivation through the SIRT1/NFjB pathway. FEBS Lett 2012;586(23):4203-7
   PubMed Web of Science ®Google Scholar
• Mogilyansky E, Rigoutsos I. The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ 2013;20(12):1603-14
   PubMed Web of Science ®Google Scholar
• Luo T, Cui S, Bian C, Yu X. Crosstalk between TGF-β/Smad3 and BMP/BMPR2 signaling pathways via miR-17-92 cluster in carotid artery restenosis. Mol Cell Biochem 2014;389(1-2):169-76
   PubMed Web of Science ®Google Scholar
• Sato Y. Is histone deacetylase-9-MicroRNA-17∼92 cluster a novel axis for angiogenesis regulation? Arterioscler Thromb Vasc Biol 2013;33(3):445-6
   PubMed Web of Science ®Google Scholar
• Patel V, Williams D, Hajarnis S, et al. miR-17∼92 miRNA cluster promotes kidney cyst growth in polycystic kidney disease. Proc Natl Acad Sci USA 2013;110(26):10765-70
   PubMed Web of Science ®Google Scholar
• Musumeci M, Coppola V, Addario A, et al. Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. Oncogene 2011;30(41):4231-42
   PubMed Web of Science ®Google Scholar
• Cheng L, Luo S, Jin C, et al. FUT family mediates the multidrug resistance of human hepatocellular carcinoma via the PI3K/Akt signaling pathway. Cell Death Dis 2013;4:e923
   PubMedGoogle Scholar
• Bernardi C, Soffientini U, Piacente F, Tonetti MG. Effects of microRNAs on fucosyltransferase 8 (FUT8) expression in hepatocarcinoma cells. PLoS ONE 2013;8(10):e76540
   PubMedGoogle Scholar
• Wang M, Wang J, Kong X, et al. MiR-198 represses tumor growth and metastasis in colorectal cancer by targeting fucosyl transferase 8. Sci Rep 2014;4:6145
   PubMed Web of Science ®Google Scholar
• Gargalionis AN, Korkolopoulou P, Farmaki E, et al. Polycystin-1 and polycystin-2 are involved in the acquisition of aggressive phenotypes in colorectal cancer. Int J Cancer 2015;136(7):1515-27
   PubMed Web of Science ®Google Scholar
• Patel V, Williams D, Hajarnis S, et al. miR-17∼92 miRNA cluster promotes kidney cyst growth in polycystic kidney disease. Proc Natl Acad Sci USA 2013;110(26):10765-70
   PubMed Web of Science ®Google Scholar
• Li X. Epigenetics and autosomal dominant polycystic kidney disease. Biochim Biophys Acta 2011;1812(10):1213-18
   PubMed Web of Science ®Google Scholar
• Masola V, Gambaro G, Tibaldi E, et al. Heparanase and syndecan-1 interplay orchestrates fibroblast growth factor-2-induced epithelial-mesenchymal transition in renal tubular cells. J Biol Chem 2012;287(2):1478-88
   PubMed Web of Science ®Google Scholar
• Musumeci M, Coppola V, Addario A, et al. Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. Oncogene 2011;30(41):4231-42
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144(5):646-74
   PubMed Web of Science ®Google Scholar
• Borbone E, De Rosa M, Siciliano D, et al. Up-regulation of miR-146b and down-regulation of miR-200b contribute to the cytotoxic effect of histone deacetylase inhibitors on ras-transformed thyroid cells. J Clin Endocrinol Metab 2013;98(6):E1031-40
   PubMed Web of Science ®Google Scholar
• Gryder BE, Sodji QH, Oyelere AK. Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Med Chem 2012;4(4):505-24
   PubMed Web of Science ®Google Scholar
• Shi B, Xu W. The development and potential clinical utility of biomarkers for HDAC inhibitors. Drug Discov Ther 2013;7(4):129-36
   PubMedGoogle Scholar
• Shin S, Lee EM, Cha HJ, et al. MicroRNAs that respond to histone deacetylase inhibitor SAHA and p53 in HCT116 human colon carcinoma cells. Int J Oncol 2009;35(6):1343-52
   PubMed Web of Science ®Google Scholar
• Humphreys KJ, Cobiac L, Le Leu RK, et al. Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster. Mol Carcinog 2013;52(6):459-74
   PubMed Web of Science ®Google Scholar
• Lee EM, Shin S, Cha HJ, et al. Suberoylanilide hydroxamic acid (SAHA) changes microRNA expression profiles in A549 human non-small cell lung cancer cells. Int J Mol Med 2009;24(1):45-50
   PubMed Web of Science ®Google Scholar
• New M, Olzscha H, La Thangue NB. HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol 2012;6(6):637-56
   PubMed Web of Science ®Google Scholar
• Musumeci M, Coppola V, Addario A, et al. Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. Oncogene 2011;30(41):4231-42
   PubMed Web of Science ®Google Scholar
• Matthias P. Too much or too little, how much HDAC activity is good for you? Blood 2013;121(11):1930-1
   PubMed Web of Science ®Google Scholar
• Lemoine M, Younes A. Histone deacetylase inhibitors in the treatment of lymphoma. Discov Med 2010;10(54):462-70
   PubMed Web of Science ®Google Scholar
• Lepore I, Dell’Aversana C, Pilyugin M, et al. HDAC inhibitors repress BARD1 isoform expression in acute myeloid leukemia cells via activation of miR-19a and/or b. PLoS ONE 2013;8(12):e83018
   PubMedGoogle Scholar
• Henrici A, Montalbano R, Neureiter D, et al. The pan-deacetylase inhibitor panobinostat suppresses the expression of oncogenic miRNAs in hepatocellular carcinoma cell lines. Mol Carcinog 2013. [ Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Sampath D, Liu C, Vasan K, et al. Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. Blood 2012;119(5):1162-72
   PubMed Web of Science ®Google Scholar
• Zhang Z, Convertini P, Shen M, et al. Valproic acid causes proteasomal degradation of DICER and influences miRNA expression. PLoS ONE 2013;8(12):e82895
   PubMed Web of Science ®Google Scholar
• Hunsberger JG, Fessler EB, Wang Z, et al. Post-insult valproic acid-regulated microRNAs: potential targets for cerebral ischemia. Am J Transl Res 2012;4(3):316-32
   PubMed Web of Science ®Google Scholar
• Aluru N, Deak KL, Jenny MJ, Hahn ME. Developmental exposure to valproic acid alters the expression of microRNAs involved in neurodevelopment in zebrafish. Neurotoxicol Teratol 2013;40:46-58
   PubMed Web of Science ®Google Scholar
• Kitamura T, Connolly K, Ruffino L, et al. The therapeutic effect of histone deacetylase inhibitor PCI-24781 on gallbladder carcinoma in BK5.erbB2 mice. J Hepatol 2012;57(1):84-91
   PubMed Web of Science ®Google Scholar
• Wang S, Huang J, Lyu H, et al. Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells. Cell Death Dis 2013;4:e556
   PubMed Web of Science ®Google Scholar
• Takai N, Narahara H. Preclinical studies of chemotherapy using histone deacetylase inhibitors in endometrial cancer. Obstet Gynecol Int 2010;2010:923824
   PubMedGoogle Scholar